Cargando…

High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis

Background: This study explores the association of neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), and platelet-to-lymphocyte (PLR) ratios with the 3-month treatment response and persistence of tumor necrosis factor-alpha (TNF-α) blockers in patients with ankylosing spondylitis (AS). M...

Descripción completa

Detalles Bibliográficos
Autores principales: Moon, Dong-Hyuk, Kim, Aran, Song, Byung-Wook, Kim, Yun-Kyung, Kim, Geun-Tae, Ahn, Eun-Young, So, Min-Wook, Lee, Seung-Geun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055887/
https://www.ncbi.nlm.nih.gov/pubmed/36986479
http://dx.doi.org/10.3390/ph16030379
_version_ 1785015986457411584
author Moon, Dong-Hyuk
Kim, Aran
Song, Byung-Wook
Kim, Yun-Kyung
Kim, Geun-Tae
Ahn, Eun-Young
So, Min-Wook
Lee, Seung-Geun
author_facet Moon, Dong-Hyuk
Kim, Aran
Song, Byung-Wook
Kim, Yun-Kyung
Kim, Geun-Tae
Ahn, Eun-Young
So, Min-Wook
Lee, Seung-Geun
author_sort Moon, Dong-Hyuk
collection PubMed
description Background: This study explores the association of neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), and platelet-to-lymphocyte (PLR) ratios with the 3-month treatment response and persistence of tumor necrosis factor-alpha (TNF-α) blockers in patients with ankylosing spondylitis (AS). Methods: This retrospective cohort study investigated 279 AS patients who were newly initiated on TNF-α blockers between April 2004 and October 2019 and 171 sex- and age-matched healthy controls. Response to TNF-α blockers was defined as a reduction in the Bath AS Disease Activity Index of ≥50% or 20 mm, and persistence referred to the time interval from the initiation to discontinuation of TNF-α blockers. Results: Patients with AS had significantly increased NLR, MLR, and PLR ratios as compared to controls. The frequency of non-response at 3 months was 3.7%, and TNF-α blockers’ discontinuation occurred in 113 (40.5%) patients during the follow-up period. A high baseline NLR but not high baseline MLR and PLR showed an independently significant association with a higher risk of non-response at 3 months (OR = 12.3, p = 0.025) and non-persistence with TNF-α blockers (HR = 1.66, p = 0.01). Conclusions: NLR may be a potential marker for predicting the clinical response and persistence of TNF-α blockers in AS patients.
format Online
Article
Text
id pubmed-10055887
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100558872023-03-30 High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis Moon, Dong-Hyuk Kim, Aran Song, Byung-Wook Kim, Yun-Kyung Kim, Geun-Tae Ahn, Eun-Young So, Min-Wook Lee, Seung-Geun Pharmaceuticals (Basel) Article Background: This study explores the association of neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), and platelet-to-lymphocyte (PLR) ratios with the 3-month treatment response and persistence of tumor necrosis factor-alpha (TNF-α) blockers in patients with ankylosing spondylitis (AS). Methods: This retrospective cohort study investigated 279 AS patients who were newly initiated on TNF-α blockers between April 2004 and October 2019 and 171 sex- and age-matched healthy controls. Response to TNF-α blockers was defined as a reduction in the Bath AS Disease Activity Index of ≥50% or 20 mm, and persistence referred to the time interval from the initiation to discontinuation of TNF-α blockers. Results: Patients with AS had significantly increased NLR, MLR, and PLR ratios as compared to controls. The frequency of non-response at 3 months was 3.7%, and TNF-α blockers’ discontinuation occurred in 113 (40.5%) patients during the follow-up period. A high baseline NLR but not high baseline MLR and PLR showed an independently significant association with a higher risk of non-response at 3 months (OR = 12.3, p = 0.025) and non-persistence with TNF-α blockers (HR = 1.66, p = 0.01). Conclusions: NLR may be a potential marker for predicting the clinical response and persistence of TNF-α blockers in AS patients. MDPI 2023-03-01 /pmc/articles/PMC10055887/ /pubmed/36986479 http://dx.doi.org/10.3390/ph16030379 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Moon, Dong-Hyuk
Kim, Aran
Song, Byung-Wook
Kim, Yun-Kyung
Kim, Geun-Tae
Ahn, Eun-Young
So, Min-Wook
Lee, Seung-Geun
High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis
title High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis
title_full High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis
title_fullStr High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis
title_full_unstemmed High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis
title_short High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis
title_sort high baseline neutrophil-to-lymphocyte ratio could serve as a biomarker for tumor necrosis factor-alpha blockers and their discontinuation in patients with ankylosing spondylitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055887/
https://www.ncbi.nlm.nih.gov/pubmed/36986479
http://dx.doi.org/10.3390/ph16030379
work_keys_str_mv AT moondonghyuk highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis
AT kimaran highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis
AT songbyungwook highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis
AT kimyunkyung highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis
AT kimgeuntae highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis
AT ahneunyoung highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis
AT sominwook highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis
AT leeseunggeun highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis